PLK1 and neoplasm: Currently, PLK1 inhibitors are being evaluated in registered clinical trials, namely volasertib (BI-6727) which was reported to have clinical response and TAK-960, which possesses the highest specificity towards PLK1, and inhibits the growth of tumor cells in vitro and in vivo independently of MDR1 expression [41].